EUVIMEDEUVIMED entdecken
Crossref

Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels

Kathryn Gazelakis iD, Isabel Chu, Catherine Martin, Miles P Sparrow iD

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Kathryn Gazelakis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Tumor Necrosis Factor Inhibitors, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory bowel disease (IBD) therapies now utilise higher doses of immunomodulatory and biologic therapies, predisposing patients to an increased risk of infections.

Aims

We aimed to determine whether infections were associated with high anti‐tumour necrosis factor (TNF) drug levels in IBD and to quantify the risk and consequences of infections.

Methods

Two retrospective studies were performed, a descriptive cohort study and a matched case–control study. For the matched case–control study, cases of infection occurring on anti‐TNF agents were matched in a 1:2 ratio to controls of anti‐TNF treated patients without infections.

Results

In the descriptive study, 76 infections occurred in 60 patients, including 49 bacterial, 24 viral, four fungal and four parasitic. Of these, 61 (80.3%) were on biologics, 49 (64.5%) on immunomodulators and 11 (14.5%) on corticosteroids. Thirty‐four (44.7%) were on combination therapy, 27 (35.5%) on biologic monotherapy and 15 (19.7%) on immunomodulator monotherapy. Median anti‐TNF drug levels in infection cases were 3.9 μg/mL for infliximab and 6.0 μg/mL for adalimumab. In the case–control study, 32 cases of infection in 27 anti‐TNF treated patients were matched with 64 anti‐TNF treated controls without infections. Among infection cases, 59.5% were on combination therapy versus 40.6% on biologic monotherapy ( P = 0.59). Median drug levels for cases and controls respectively were 3.9 μg/mL versus 5.5 μg/mL for infliximab ( P = 0.72) and 6.0 μg/mL versus 9.9 μg/mL for adalimumab ( P = 0.34).

Conclusion

Infections in patients with IBD were common, and the risk was highest with combination therapy. Infections were not associated with high serum anti‐TNF levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor InhibitorsInflammatory Bowel DiseasesHumansAdalimumabInfliximabCohort StudiesRetrospective StudiesCase-Control StudiesTumor Necrosis Factor-alphaImmunologic FactorsAdjuvants, ImmunologicBiological Therapy

Stichwörter der Autor:innen

anti-TNF levelinfectioninflammatory bowel disease

Substanzen

AdalimumabInfliximabTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alphaImmunologic FactorsAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Victoria, Australia.
  • Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia.
  • Data Science and AI Platform, Monash e-Research Centre, Melbourne, Victoria, Australia.

ORCID-Profile: Kathryn Gazelakis, Miles P Sparrow

Zitieren

APA

Gazelakis, K., Chu, I., Martin, C., & Sparrow, M. P. (2024). Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels. Internal Medicine Journal. https://doi.org/10.1111/imj.16105

Vancouver

Gazelakis K, Chu I, Martin C, Sparrow MP. Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels. Internal Medicine Journal. 2024. doi:10.1111/imj.16105

BibTeX
@article{Gazelakis2024,
  author = {Gazelakis, Kathryn and Chu, Isabel and Martin, Catherine and Sparrow, Miles P},
  title = {Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16105}
}
Kostenlos starten →